Literature DB >> 7992827

Cost-effectiveness considerations for managed care systems: treating depression in primary care.

B H McFarland1.   

Abstract

This article addresses the management of depression in primary care from the perspective of a health maintenance organization. The rise of managed care systems is briefly discussed with reference to their impact on choice of treatment strategies. Cost-effectiveness considerations pertinent to a health maintenance organization are reviewed. A simplified protocol for the treatment of depression with paroxetine or imipramine in the primary care sector is presented and used as an example of cost calculations. Given the assumptions used in this cost-effectiveness model, it appears that the costs of treating depression in primary care with paroxetine are approximately equal to those found with the use of imipramine. Higher acquisition costs of paroxetine are balanced by the greater labor costs associated with imipramine.

Entities:  

Mesh:

Year:  1994        PMID: 7992827     DOI: 10.1016/0002-9343(94)90363-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  7 in total

1.  The added costs of depression to medical care.

Authors:  K Franco; M Tamburino; N Campbell; J Zrull; C Evans; D Bronson
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

Review 2.  Selective serotonin reuptake inhibitors. Assessment for formulary inclusion.

Authors:  B H Guze
Journal:  Pharmacoeconomics       Date:  1996-05       Impact factor: 4.981

Review 3.  Formulary restriction of selective serotonin reuptake inhibitors for depression: potential pitfalls.

Authors:  P L Hensley; H G Nurnberg
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 4.  Sertraline. A pharmacoeconomic evaluation of its use in depression.

Authors:  R Davis; M I Wilde
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

5.  Recent care of common mental disorders in the United States : prevalence and conformance with evidence-based recommendations.

Authors:  P S Wang; P Berglund; R C Kessler
Journal:  J Gen Intern Med       Date:  2000-05       Impact factor: 5.128

6.  Practice guidelines and late-life depression assessment in long-term care.

Authors:  D A Banazak; P B Mullan; J C Gardiner; S Rajagopalan
Journal:  J Gen Intern Med       Date:  1999-07       Impact factor: 5.128

Review 7.  Milnacipran. A review of its use in depression.

Authors:  C M Spencer; M I Wilde
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.